ST1571: A paradigm of new agents for cancer therapeutics

被引：156

作者：

Mauro, MJ

O'Dwyer, M

Heinrich, MC

Druker, BJ

机构：

[1] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Leukemia Program, Portland, OR 97201 USA

[2] Vet Affairs Med Ctr, Portland, OR USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2002年 / 20卷 / 01期

关键词：

D O I：

10.1200/JCO.20.1.325

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ST1571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose selection, optimizing therapy, and predicting response, as are possible mechanisms of resistance to ST1571. Lastly, the potential use of ST1571 in other malignancies and the translation of this paradigm to other malignancies are explored. (C) 2001 by American Society of Clinical Oncology.

引用

页码：325 / 334

页数：10

共 65 条

[1] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[2]

[Anonymous], 2001, P AM SOC CLIN ONCOL

[3]

BEDI A, 1994, BLOOD, V83, P2038

[4] THE CHRONIC MYELOGENOUS LEUKEMIA SPECIFIC P210-PROTEIN IS THE PRODUCT OF THE BCR/ABL HYBRID GENE [J].

BEN-NERIAH, Y ;

DALEY, GQ ;

MESMASSON, AM ;

WITTE, ON ;

BALTIMORE, D .

SCIENCE, 1986, 233 (4760) :212-214

[5]

Beran M, 1998, CLIN CANCER RES, V4, P1661

[6]

Blanke CD, 2001, P AM SOC CLIN ONCOL, p1a

[7]

Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139

[8] CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J].

Carroll, M ;

OhnoJones, S ;

Tamura, S ;

Buchdunger, E ;

Zimmermann, J ;

Lydon, NB ;

Gilliland, DG ;

Druker, BJ .

BLOOD, 1997, 90 (12) :4947-4952

[9] INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].

DALEY, GQ ;

VANETTEN, RA ;

BALTIMORE, D .

SCIENCE, 1990, 247 (4944) :824-830

[10] ACTIVATION OF THE C-ABL-ONCOGENE BY VIRAL TRANSDUCTION OR CHROMOSOMAL TRANSLOCATION GENERATES ALTERED C-ABL-PROTEINS WITH SIMILAR INVITRO KINASE PROPERTIES [J].

DAVIS, RL ;

KONOPKA, JB ;

WITTE, ON .

MOLECULAR AND CELLULAR BIOLOGY, 1985, 5 (01) :204-213

← 1 2 3 4 5 6 7 →